Solid Biosciences (NASDAQ:SLDB) COO David Howton Sells 7,469 Shares

Solid Biosciences Inc. (NASDAQ:SLDB) COO David Howton sold 7,469 shares of the business’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $5.82, for a total transaction of $43,469.58. Following the transaction, the chief operating officer owned 105,077 shares in the company, valued at $611,548.14. This represents a 6.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Solid Biosciences Stock Performance

Solid Biosciences stock opened at $5.92 on Thursday. Solid Biosciences Inc. has a fifty-two week low of $2.41 and a fifty-two week high of $7.37. The stock’s 50 day simple moving average is $5.95 and its two-hundred day simple moving average is $5.68. The stock has a market cap of $461.23 million, a price-to-earnings ratio of -2.38 and a beta of 2.67.

Hedge Funds Weigh In On Solid Biosciences

A number of hedge funds have recently added to or reduced their stakes in SLDB. Legal & General Group Plc lifted its position in Solid Biosciences by 208.6% in the 2nd quarter. Legal & General Group Plc now owns 6,011 shares of the company’s stock valued at $29,000 after acquiring an additional 4,063 shares in the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company’s stock valued at $33,000 after purchasing an additional 4,534 shares in the last quarter. Creative Planning purchased a new stake in shares of Solid Biosciences during the second quarter valued at $57,000. Russell Investments Group Ltd. increased its holdings in Solid Biosciences by 142.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 10,211 shares of the company’s stock worth $63,000 after buying an additional 5,991 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in Solid Biosciences by 233.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 15,113 shares of the company’s stock worth $74,000 after buying an additional 10,585 shares during the last quarter. 81.46% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Solid Biosciences

Here are the key news stories impacting Solid Biosciences this week:

• Neutral Sentiment: Coverage explaining the intraday lift — AAII published an item titled “Why Solid Biosciences Inc.’s (SLDB) Stock Is Up 7.64%” that summarizes market reaction and likely drivers for the rise; read it for context. Why SLDB Stock Is Up
• Neutral Sentiment: Technical and valuation context: 12‑month range roughly $2.41–$7.37, market cap ≈ $461M, negative P/E (loss-making), 50‑day SMA ~$5.95 and 200‑day SMA ~$5.68 — the stock is trading near its recent highs, so momentum/coverage can amplify moves.
• Negative Sentiment: CEO Alexander Cumbo sold 16,644 shares at an average $5.82 (≈ $96,868); his post‑sale holding is 235,405 shares (down ~6.6%). Filing: CEO Sale Filing
• Negative Sentiment: CFO Kevin Tan sold 5,404 shares at an average $5.82 (≈ $31,451); post‑sale holding 99,422 shares (down ~5.2%). Filing: CFO Sale Filing
• Negative Sentiment: COO David T. Howton sold 7,469 shares at $5.82 (≈ $43,470); post‑sale holding 105,077 shares (down ~6.6%). Filing: COO Sale Filing
• Negative Sentiment: CTO Paul Herzich sold 3,616 shares at $5.82 (≈ $21,045); post‑sale holding 72,638 shares (down ~4.7%). Filing: CTO Sale Filing
• Negative Sentiment: Director Ilan Ganot sold 2,658 shares at $5.82 (≈ $15,470); post‑sale holding 27,474 shares (down ~8.8%). Filing: Director Sale Filing
• Negative Sentiment: Insider Jessie Hanrahan sold 4,134 shares at $5.82 (≈ $24,060); post‑sale holding 74,318 shares (down ~5.3%). Filing: Insider Sale Filing

Analysts Set New Price Targets

A number of research firms have recently weighed in on SLDB. Citigroup reaffirmed a “market outperform” rating on shares of Solid Biosciences in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. JPMorgan Chase & Co. decreased their target price on shares of Solid Biosciences from $13.00 to $11.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Chardan Capital reiterated a “buy” rating and set a $15.00 target price on shares of Solid Biosciences in a report on Tuesday, November 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $16.00 price target on shares of Solid Biosciences in a research note on Monday, February 9th. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.70.

Solid Biosciences Company Profile

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.